How long can you live with a stent in your heart?

A coronary stent does not come with an expiration date, and there is no single number that tells you how many years of life one adds. The stent itself is a permanent metal scaffold that stays in your artery for life, and the real question is how well the underlying heart disease is managed after placement. Ten-year survival data from randomized trials show that roughly three out of four patients who receive stents are still alive a decade later, though their mortality risk remains higher than that of the general population. What determines where you fall in that range has less to do with the stent and more to do with your other health conditions, whether you keep taking your medications, and how aggressively you manage risk factors like smoking and cholesterol.

What the Long-Term Survival Numbers Actually Show

The most direct evidence comes from studies that followed stent patients for a decade or longer. An analysis of two randomized trials involving 2,743 patients who received coronary stents found that about 25% died within ten years of follow-up. Compared with the general population of similar age, these patients had a 76% higher ten-year mortality risk overall.¹ That gap reflects the fact that people who need stents already have coronary artery disease, which carries its own ongoing risks regardless of the procedure.

One of the longest follow-up studies tracked patients who received bare-metal stents for 15 to 20 years. By the 15-year mark, about 45% of those patients had died from any cause, and roughly one in five deaths was specifically cardiac.² Those numbers sound alarming on their own, but it is worth remembering that the patients in that study were aging over those 15 years, and many of the deaths were from causes unrelated to the heart. In the ten-year data, roughly 40% of all deaths were non-cardiovascular.¹ Having a stent does not mean your heart is necessarily what gets you in the end.

The Stent Stays Forever, but That Is Not Usually the Problem

Commercially available coronary stents are made of metal alloys and do not degrade. They remain in the artery permanently.³ Over time, the body’s healing response covers the metal struts with a thin layer of tissue, essentially incorporating the stent into the artery wall. This process involves several phases: a brief initial clotting reaction, an inflammatory response, and then a period where smooth muscle cells migrate inward and build new tissue over the stent struts.⁴ In most patients, this heals uneventfully. But in some, the tissue overgrowth narrows the artery again, a problem called in-stent restenosis. And if a blood clot forms on the stent before that healing is complete, that is stent thrombosis, a much rarer but more dangerous event.

These two complications are the main concerns with a stent that sits in your body for decades. The good news is that newer stent designs have reduced both risks significantly.

How Stent Type Affects Your Long-Term Odds

There are two main categories of permanent coronary stents: bare-metal stents and drug-eluting stents. Drug-eluting stents are coated with medication that slowly releases into the artery wall, inhibiting the excessive tissue growth that leads to re-narrowing. Most stents placed today are drug-eluting.

A large network analysis combining data from over 52,000 patients across 51 trials found that newer-generation drug-eluting stents, particularly those coated with everolimus, had lower rates of death, stent thrombosis, and heart attacks compared with bare-metal stents and older drug-eluting designs.⁵ A head-to-head trial comparing everolimus-eluting stents against earlier drug-eluting designs confirmed this: the rate of stent thrombosis beyond one year was roughly a third of what it was with older models.⁶

The practical difference is most visible when the stent is placed in a bypass graft rather than a native artery. In a randomized trial of stents placed in saphenous vein grafts, drug-eluting stents cut the five-year rate of major adverse cardiac events nearly in half compared with bare-metal stents.⁷ In the general population, however, a large trial found that the six-year risk of death, heart attack, or stroke was essentially identical between drug-eluting and bare-metal stents. The difference was in the need for repeat procedures: drug-eluting stents reduced the six-year repeat-revascularization rate by about three percentage points.⁸ So drug-eluting stents keep you out of the catheterization lab more often, even if the overall survival benefit over bare-metal stents is modest in average-risk patients.

Stent Thrombosis Years Later

The most feared long-term complication is very late stent thrombosis, a blood clot that forms on the stent more than a year after placement. When it happens, it typically causes a heart attack. The reassuring part is that it is rare with modern stents. In a large prospective study, everolimus-eluting stents had a very-late-thrombosis rate of about 0.6 per 100 person-years, roughly a third of the rate seen with older paclitaxel-eluting stents.⁶

But rare does not mean impossible. Case reports have documented stent thrombosis occurring more than 12 years after a first-generation drug-eluting stent was placed.⁹ Events that far out are extremely uncommon, and they tend to involve older stent designs or patients with specific risk factors such as lesions in a particular location or previous in-stent restenosis.¹⁰ The risk is real enough to matter, but not so common that it should define your outlook after getting a stent.

When the Stent Narrows Again

In-stent restenosis is far more common than thrombosis. Unlike a clot, which is sudden and dangerous, restenosis is a gradual process in which scar-like tissue builds up inside the stent over months to years, slowly reducing blood flow. When it happens, it usually means another procedure.

Current options for treating restenosis include drug-coated balloon angioplasty and placement of a second drug-eluting stent inside the first. A randomized trial comparing a paclitaxel-coated balloon against an uncoated balloon for in-stent restenosis found that the drug-coated version cut the one-year rate of target lesion problems by about 40%.¹¹ However, a large collaborative meta-analysis found that at three years, re-implanting a drug-eluting stent outperformed drug-coated balloons for preventing repeat narrowing by about a third.¹² The bottom line is that restenosis is treatable, and having it does not mean the stent “failed” in a life-threatening way. It is more of a maintenance issue.

Risk Factors That Actually Shorten Life After Stenting

The stent holds the artery open, but it does nothing to treat the systemic disease that narrowed the artery in the first place. Diabetes, kidney disease, and smoking are the three biggest modifiers of long-term outcomes after stenting, and their effects are dramatic.

In a large cooperative study of patients who received stents during a heart attack, those with diabetes had more than double the death rate of non-diabetic patients over roughly three years of follow-up. They also had higher rates of stent thrombosis and repeat heart attacks, and those differences held even after adjusting for other baseline differences.¹³ For patients with severe disease in multiple arteries, a pooled analysis found that stenting and bypass surgery produced similar survival rates in diabetic patients over about five and a half years, though stented patients needed substantially more repeat procedures regardless of whether they had diabetes.¹⁴

Chronic kidney disease carries a similarly outsized impact. Seven-year survival after stenting dropped from about 89% in patients with normal kidney function to roughly 65% in those with impaired kidneys, and kidney disease independently doubled the risk of dying or having a heart attack.¹⁵ The worse the kidney function, the higher the risk: patients with severe kidney disease or those on dialysis had the greatest increase in adverse events.¹⁶

Smoking is the one major risk factor you can eliminate entirely. A study of over 22,000 patients followed for ten years after drug-eluting stent placement found that smokers had a 45% higher adjusted risk of dying from any cause and more than double the risk of stent thrombosis compared with nonsmokers.¹⁷ A separate study of Chinese men found that persistent smokers had roughly two and a half times the death rate of quitters, and quitting brought the risk down to nearly the level of never-smokers.¹⁸ If you want a single action that most improves your odds with a stent in place, quitting smoking is it.

Why Your Medications Matter as Much as the Stent

The first year after stent placement is when the device is most vulnerable to clotting, because the healing tissue has not yet fully covered the metal struts. That is why you are put on two blood-thinning medications, typically aspirin plus a second antiplatelet drug, for a period after the procedure. This dual therapy clearly improves the combined one-year outcome for death, heart attack, and stroke.¹⁹ Stopping these medications early, especially within the first several months, is one of the strongest predictors of stent thrombosis. If you are facing surgery or a dental procedure that makes a doctor want to stop your blood thinners, that conversation needs to include whoever placed your stent.

Statins are the other class of medication with striking long-term benefits for stented patients. Beyond their well-known role in lowering cholesterol, statins appear to directly improve the way the artery heals around the stent. High-dose statin therapy resulted in better tissue coverage of stent struts at 12 months compared with lower-dose therapy.²⁰ Patients on statins also had a significantly lower rate of late re-narrowing after stenting, particularly when their LDL cholesterol was driven below 100 mg/dL.²¹ And across multiple trials, statin therapy does not merely slow the buildup of plaque in arteries; a pooled analysis showed it can actually cause some regression of existing plaque.²² Skipping statins after stenting because your cholesterol “isn’t that bad” misses the point. The benefit goes beyond the numbers on a lipid panel.

Exercise and Cardiac Rehabilitation

Structured cardiac rehabilitation, the supervised exercise and education programs offered after a heart procedure, provides measurable protection of the stented artery. Two studies found that patients who completed cardiac rehab had about 35% less re-narrowing inside the stent at nine months compared with patients who received usual care alone.²³ ²⁴ The benefit was consistent regardless of which generation of drug-eluting stent was used. Cardiac rehab also improved smoking rates, cholesterol profiles, weight, depression scores, and exercise capacity in these patients, so the stent-specific benefit is likely part of a broader improvement in cardiovascular health.

Despite the evidence, cardiac rehab is underused. Many patients either are not referred, cannot access a program, or drop out. If you have had a stent placed and have not been offered rehab, it is worth asking about.

Do Stents Actually Help You Live Longer?

This is one of the most counterintuitive findings in cardiology, and it tends to catch people off guard. For patients with stable coronary artery disease, meaning narrowed arteries but no acute heart attack, stenting does not appear to extend life compared with medications alone. A meta-analysis of randomized trials involving over 7,200 patients with stable disease found that the death rate was essentially identical whether patients received a stent plus medication or medication alone.²⁵

The landmark COURAGE trial made this point in 2007, showing no difference in death, heart attack, or stroke over about four and a half years between the stent group and the medical-therapy-only group in patients with stable ischemic heart disease.²⁶ Extended follow-up of those same patients out to a median of about 12 years showed no survival benefit from stenting either: roughly 25% of patients had died in both groups.²⁷

This does not mean stents are useless. In a heart attack, stents are life-saving. And even in stable disease, stents relieve angina, the chest pain and tightness that come with exertion. A trial comparing stenting and bypass surgery in patients with extensive coronary disease found that both treatments provided substantial and sustained quality-of-life improvements over five years, with bypass offering slightly greater angina relief.²⁸ For many patients, that relief from daily chest pain is reason enough. But if you have stable disease and no symptoms that limit your life, the survival argument for stenting is weak. Good medical therapy may be all you need.

Stents Versus Bypass Surgery

When disease is extensive, involving three vessels or the main trunk of the left coronary artery, the decision between stents and open-heart bypass surgery becomes a serious discussion. A ten-year comparison found that the adjusted risks of death were similar between the two approaches regardless of whether the patient had diabetes.²⁹ The recurring trade-off is the same one seen in simpler disease: stenting is less invasive and has a quicker recovery, but it comes with a substantially higher chance of needing another procedure down the line. In a pooled analysis, stented patients had more than triple the rate of repeat revascularization compared with bypass patients.¹⁴

That repeat-procedure burden matters to how you experience life with a stent. It does not usually mean more danger, but it does mean more catheterizations, more recovery periods, and more medication adjustments. For younger patients with decades ahead of them, the calculus may favor getting bypass surgery done once. For older patients or those who cannot safely undergo open-heart surgery, stenting provides a similar survival profile with less upfront risk.

Monitoring a Stent Over the Years

After the first year, follow-up for most stent patients involves periodic office visits, stress tests when symptoms change, and attention to risk-factor management. Routine invasive angiography just to check on a stent that is not causing symptoms is not recommended. CT coronary angiography has evolved into a useful noninvasive option when there is a clinical question about whether a stent has re-narrowed. It has a negative predictive value around 98% for ruling out significant in-stent restenosis, meaning if the CT scan looks clear, you can be highly confident the stent is open.³⁰ The technology works better with larger stents and in vessels that are not heavily calcified, so your doctor may still recommend a stress test or invasive look depending on your anatomy.

The Future of Stents That Disappear

One of the most active areas of research involves stents designed to dissolve after they have done their job. The idea is appealing: prop the artery open during the critical healing phase, then vanish, leaving behind a normal artery that can flex and respond to changes in blood flow. Early polymer-based bioresorbable scaffolds, however, ran into trouble. A meta-analysis of seven randomized trials found that one widely studied bioresorbable scaffold had a nearly threefold higher rate of device clotting compared with a standard metallic drug-eluting stent, and that elevated risk extended beyond the first year.³¹ That product was eventually pulled from the market.

Newer designs using magnesium, iron, and zinc alloys are showing more promise. Magnesium-based stents have demonstrated full absorption within about 12 months, with low rates of re-narrowing in early trials. Iron-based stents take longer, fully dissolving over roughly three years, and have shown favorable mid-term safety data.³² These are still in relatively early stages, and it will be years before we have the kind of long-term data available for conventional metal stents. But they represent a plausible future in which the question of living with a permanent implant becomes less relevant.

Sex Differences in Outcomes

Women who receive coronary stents have consistently worse long-term outcomes than men, a pattern that persists even after adjusting for other risk factors. In the ten-year trial analysis mentioned earlier, roughly 29% of women had died compared with 23% of men. Compared with the general population of their own sex and age, women who received stents had a standardized mortality ratio of 2.13, meaning their risk of dying was more than double that of age-matched women without coronary disease. For men, that ratio was 1.63. Interestingly, the difference was not driven by cardiac causes specifically: the proportions of cardiac, vascular, and non-cardiovascular deaths were similar between men and women.¹ The gap likely reflects the fact that women tend to develop coronary artery disease later in life, often with more comorbidities at the time of stenting. It is not that stents work less well in women, but that women who need them tend to be sicker at baseline.